Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

Pamela Munster, Ian E. Krop, Patricia LoRusso, Cynthia Ma, Barry A. Siegel, Anthony F. Shields, István Molnár, Thomas J. Wickham, Joseph Reynolds, Karen Campbell, Bart S. Hendriks, Bambang S. Adiwijaya, Elena Geretti, Victor Moyo, Kathy D. Miller

Research output: Contribution to journalArticlepeer-review

93 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science